EBR Systems, Inc. · ASX:EBR
EBR Systems — Investor Presentation (June 2026)
50 slides from EBR Systems's investor presentation, Jun 4, 2026
Slide 1: EBR Fundraising Presentation
For personal use only EBR Fundraising Presentation JUNE 2026
Slide 2: Disclaimer
Disclaimer Important Notices and Disclaimer Investment risk THIS DOCUMENT IS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO ANY U.S. An investment in EBR is subject to known and unknown risks, some of which are beyond the control of EBR For personal use only PERSONS, OR IN ANY OTHER JURI
Slide 3: Disclaimer
Disclaimer Past performance This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the Past performance, including the pro-forma historical information in this presentation is given for illustrative United States. The New CDIs have not been, and w
Slide 4: Disclaimer
Disclaimer Disclaimer You acknowledge and agree that determination of eligibility of investors for the purposes of the Capital Raise is determined by reference to a number of matters, including legal and regulatory requirements, logistical and For personal use only registry constraints and the discr
Slide 5: Executive Summary
Executive Summary • EBR’s WiSE® CRT System is the world’s smallest leadless cardiac pacing device, and provides the only option for upgrading leadless pacemakers to totally leadless Cardiac Novel Technology Resynchronisation Therapy (CRT) For personal use only • EBR WiSE CRT System has no direct com
Slide 6: Investment Highlights
Investment Highlights The future of CRT is leadless. EBR’s WiSE is the only device able to provide truly leadless solution for CRT. For personal use only Developer of the world’s first and only FDA approved leadless pacing system for heart failure with no direct competitors, and which complements ot
Slide 7: Market opportunity
For personal use only Market opportunity
Slide 8: Cardiac Rhythm Management Market
Cardiac Rhythm Management Market Comprised of three key segments For personal use only Atrial Lead Worldwide CRM Market (US$18.4bn)1 Right Ventricular Lead Left Ventricular (LV) Lead $5.6bn $6.0bn $6.7bn Cardiac Resynchronization Therapy (CRT) Implantable Cardioverter Defibrillation (ICD) Pacemakers
Slide 9: Cardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapy Landmark studies published over 25 -years have consistently shown the clinical benefits of CRT For personal use only Clinical Need for CRT • Subset of heart failure patients have a condition called ventricular dyssynchrony • The ventricles (lower chambers of the hea
Slide 10: The Clinical Need for Leadless Pacing Devices
The Clinical Need for Leadless Pacing Devices Traditional pacing, ICD and CRT systems relied on leads to deliver electrical energy to the heart, which has led to many problems. For personal use only Leads can migrate and Left Ventricle (LV) lead must fracture be placed outside the heart to avoid blo
Slide 11: The WiSE CRT System
The WiSE CRT System WiSE the first and only leadless device that addresses the limitations of traditional CRT devices by delivering leadless left ventricular endocardial pacing For personal use only WiSE provides a unique, market leading solution 1 WiSE System fills the gap • The only leadless solut
Slide 12: Market is Rapidly Adopting Leadless Devices as Standard
Market is Rapidly Adopting Leadless Devices as Standard To address limitations of transvenous leads, the wider market is moving towards leadless pacemakers and ICDs EBR’s WiSE System provides the only option for upgrading leadless pacemakers to totally leadless CRT (TLC) For personal use only Boston
Slide 13: Targeting a $5.8bn Total Addressable US Market
Targeting a $5.8bn Total Addressable US Market FDA approval opens up a significant TAM representing patients with limited or no other options For personal use only Total Addressable market (US$5.8bn)1 Acute Lead Failure Unable to implant CRT lead in a Leadless Upgrades $0.5bn new CRT patient 9k pati
Slide 14: Commercialisation strategy
For personal use only Commercialisation strategy
Slide 15: Building Momentum in the WiSE System
Building Momentum in the WiSE System EBR has achieved several key milestones and is well positioned to continue to capitalise on its existing momentum to drive further growth. Limited market release will continue through 20 26 and into 2027, with a focus on laying groundwork for broader sales covera
Slide 16: WiSE Premium Reimbursement
WiSE Premium Reimbursement As a breakthrough medical device, EBR ’s WiSE System has been granted significant reimbursement For personal use only Medicare In-patient Payment Medicare Out-patient Payment Medicare Coverage New Technology Add-On Payment Transitional Pass-Through (TPT) Transitional Cover
Slide 17: Established Commercialisation Pathway
Established Commercialisation Pathway EBR leverages its world class sales reps to pursue an established and well -trodden path to commercialisation For personal use only Experienced sales Electrophysiologist Hospital Purchase Treating Patients & reps (‘EP') Commitment Agreement Revenue Field Team Hi
Slide 18: Three Major Purchasing Agreements Announced
Three Major Purchasing Agreements Announced Strong commercial traction continued into Q2 with the signing of three major purchasing agreements For personal use only Who are HCA Healthcare? “Securing these major purchasing • The largest hospital network in the US agreements with some of the largest •
Slide 19: What clinicians are saying about the WiSE System
What clinicians are saying about the WiSE® System Potential to add EP testimonials For personal use only “ “ “ Dr Rahul Doshi, MD Devi Nair M.D. Robert C Canby M.D. Chief of Cardiovascular Medicine and Network Director of Cardiac Electrophysiology & Research, President, Texas Cardiac Arrhythmia Rese
Slide 20: World Class Manufacturing Facility
World Class Manufacturing Facility EBR is transitioning into a new state -of-the-art facility to support long -term commercial growth and scale For personal use only Significant Facility Expansion • New 11-year lease secured for 51,000 ft2 (4,751 m2) facility, including 3,610 ft2 (335 m2) cleanroom
Slide 21: Long Term Growth Strategy
Long Term Growth Strategy Long term growth opportunity targeting new patient groups, indications and geographies For personal use only Pursue new indications Product development Expand internationally Progress clinical studies to Grow addressable market Launch in select OUS1 markets expand indicatio
Slide 22: Leadership and Financials
For personal use only Leadership and Financials
Slide 23: Leadership Team
Leadership Team John Gary Doherty Erik Strandberg Michael Aimee Einstein McCutcheon CHIEF FINANCIAL OFFICER CHIEF COMMERCIAL OFFICER Hendricksen CHIEF HUMAN RESOURCES OFFICER For personal use only PRESIDENT & CHIEF CHIEF OPERATING OFFICER EXECUTIVE OFFICER • CEO since 2019 • CFO since 2023 • CCO sin
Slide 24: Summary Financials
Summary Financials Select summary financial data from Q1 2026 Form 10 -Q filed May 11, 2026– figures in US$K For personal use only 50 $2,500 Line Item 3Q 2025 4Q 2025 1Q 2026 40 $2,000 Quantity – Commercial Implants # 9 18 41 30 $1,500 20 $1,000 Revenue US$000’ 512 935 2,362 10 $500 Gross Profit US$
Slide 25: Fundraising
For personal use only Fundraising
Slide 26: Equity Raising Summary
Equity Raising Summary • A fully underwritten Offer of approximately A$150 million which comprises: For personal use only – A two-tranche institutional placement (Placement) to raise approximately $64.4 million in aggregate: – Tranche 1: approximately $29.4 million, to be placed to institutional and
Slide 27: Sources & Uses of Funds
Sources & Uses of Funds EBR is raising capital to accelerate its growth and support a pathway to cash flow break even For personal use only Sources A$m US$m Description 6% Institutional Placement 11% ANREO (entitlement offer) Total 150 108 44% Uses A$m US$m Description 22% Commercial team growth and
Slide 28: Timetable
Timetable Event Date For personal use only Trading halt and announcement of underwritten offer Thursday, 4 June 2026 Placement & Institutional Entitlement Offer Opens Thursday, 4 June 2026 Announcement of results of Placement and Institutional Entitlement Offer and recommence trading of CDIs on ASX
Slide 29: Risks
For personal use only Risks Appendix 1
Slide 30: Key risk factors
Key risk factors 1. Company Specific Risks For personal use only In addition to the general risks noted in in this Presentation, investors should be aware of the specific risks of an investment in EBR. These specific risks include, but are not limited to, those risks referred to below. 1.1 Transitio
Slide 31: Key risk factors
Key risk factors 1.4 Payor coverage For personal use only Access to adequate coverage and reimbursement for the Company's products by third-party payors is essential to the acceptance of the Company's products by its customers. The process for determining whether a payor will provide coverage for a
Slide 32: Key risk factors
Key risk factors 1.8 Manufacture of products For personal use only EBR’s products must meet stringent quality standards and it has limited experience in manufacturing its products in commercial quantities, and therefore may encounter production delays or shortfalls. Any failure to comply with applic
Slide 33: Key risk factors
Key risk factors 1.11 Legal and Regulatory requirements For personal use only The regulatory approval of the WiSE® CRT System in the United States is subject to certain post-marketing obligations and commitments to the FDA, including a prospective, real-world, observational study aimed at understand
Slide 34: Key risk factors
Key risk factors 1.15 Management resources and attracting and retaining skilled staff EBR’s long-term growth and performance is dependent on attracting and retaining highly skilled staff. Despite having structured incentive programs, there is a risk that EBR will be unable to attract and retain the
Slide 35: Key risk factors
Key risk factors 1.18 Relationships with physicians For personal use only The research, development, marketing, and sale of EBR’s products and potential new and improved products depend upon EBR maintaining working relationships with physicians. EBR relies on these professionals to provide it with c
Slide 36: Key risk factors
Key risk factors 1.21 Third party intellectual property rights disputes EBR does not believe that its activities infringe on any third party's intellectual property rights. However, in the future EBR may be subjected to infringement claims or litigation arising out of patents and pending application
Slide 37: Key risk factors
Key risk factors For personal use only 1.23 Litigation and other legal proceedings From time to time, EBR may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory invest
Slide 38: Key risk factors
Key risk factors 1.26 Healthcare fraud and abuse laws and other healthcare laws and regulations Healthcare providers, including physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any products for which EBR obtains m
Slide 39: Key risk factors
Key risk factors 1.29 Changes in U.S. and non-U.S. tax laws The tax regimes to which EBR is subject or under which it operates are unsettled and may be subject to significant change. The amount of taxes EBR pays in different jurisdictions depends on the application of the tax laws of various jurisdi
Slide 40: Key risk factors
Key risk factors 3. General Risks For personal use only There are risks associated with any stock market investment. Some of these risks are listed below. 3.1 Stock market fluctuations Stock market fluctuations in Australia and other stock markets around the world may negatively impact EBR’s CDI pri
Slide 41: International Selling Restrictions
For personal use only Appendix 2 International Selling Restrictions
Slide 42: International Selling Restrictions
International Selling Restrictions This document does not constitute an offer of CDIs in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the CDIs may not be offered or sold, in any country For personal use only outside Australia
Slide 43: International Selling Restrictions
International Selling Restrictions Singapore associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (“relevant persons”). This document and any other materials relating to the CDIs have not been, and will not be, lodged or registered The investment to which this do
Slide 44: International Selling Restrictions
International Selling Restrictions Restrictions under Regulation S under the US Securities Act Compliance Period that are consistent with the “no action” procedures. EBR’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US During the Distribution Complianc
Slide 45: International Selling Restrictions
International Selling Restrictions Requirements of any lead manager and ASX Participating Organisations shares underlying those New CDIs) not made in accordance with the provisions of Regulation S, pursuant The no-action letter requires that any lead manager and ASX Participating Organisations (brok
Slide 46: Underwriting Agreement
For personal use only Appendix 3 Underwriting Agreement
Slide 47: Underwriting Agreement
Underwriting Agreement EBR entered into an underwriting agreement with Canaccord Genuity (Australia) Limited, Morgans Corporate Limited and E&P Capital Pty Ltd (Underwriters) in respect of the Capital Raise on 4 June 2026 (Underwriting Agreement). Pursuant to the Underwriting Agreement, the Underwri
Slide 48: Underwriting Agreement
Underwriting Agreement • certain market or trading disruption events occur, including a suspension or material limitation in securities generally or any adverse change or disruption to existing financial markets, political or economic conditions of certain jurisdictions or a general moratorium on co
Slide 49: Underwriting Agreement
Underwriting Agreement The ability of an Underwriter to terminate the Underwriting Agreement in respect of some events will depend on whether in the reasonable opinion of the Underwriter the event: • has, or is likely to have, a material adverse effect on the success, marketing or settlement of the
Slide 50: Contact
For personal use only Contact: Company Investors Andrew Shute Gabriella Hold Chief Corporate Development Officer The Capital Network P: +44 7730 691421 P: +61 2 8999 3699 E: info@ebrwise.com E: gaby@thecapitalnetwork.com.au